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Introduction 
Schizophrenia is associated with cognitive deficit 
either due to the disease itself or from the side 
effects of medication. Cognition mainly the 
executive function is under the jurisdiction of 
prefrontal cortex via the influence of both 
dopamine and acetylcholine neurotransmitters 
(1,2). Antipsychotics are the notorious cause of 
cognitive deficit via two mechanisms which are D4 
and/or cholinergic receptors blockade. 
Antipsychotics dosage was negatively correlated 
with the cognition particularly on the declarative 
memory (3). A study showed that the cognition of 
schizophrenia patient is generally impaired with 
the increment of the antipsychotics dosage with or 
without anticholinergic property. But, those 
treated with antipsychotics that possess 
anticholinergic property fare even worse (4) . 
However, anticholinergic delirium associated with 
flupenthixol and benzhexol within therapeutic 
dosages have never been reported. Thereby, it is 
crucial to be vigilant of this serious adverse effect 
to accurately identify and manage the condition 
appropriately. 
 
Case Report 
This 59-year-old man was being treated for 
paranoid schizophrenia. He was on oral 
haloperidol 15mg omni nocte, oral benzhexol 2mg 
bis in die, and intramuscular flupenthixol decanoate 
60mg monthly. After two months of treatment, 
his wife noted that the patient gradually became 
forgetful. Concurrently, he exhibited signs of 
parkinsonism such as tremor, bradykinesia, and 
rigidity of the limbs. The haloperidol was tapered 
off with the impression that the extrapyramidal 
and cognitive side effects were secondary to 
excessive blockade of dopamine receptors. The 
parkinsonism completely abated after the 
increment of benzhexol to 2mg omni mane and 4mg 
omni nocte. However, he became disorientated to 
time, place, and person indicating a delirium. He 
became dependant on his wife for the activity of 
daily living. He ate less and loss 5kg weight within 
a month. He also had constipation. Physical 
examination showed dry skin and mouth, normal 
temperature and stable vital signs. The Elderly 
Cognitive Assessment Questionnaire (ECAQ) 
score was 3/11. He could  not perform the written  
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alternating sequencing task test, pentagons test, 
and clock drawing test. The full blood count, renal 
profile, liver function test, and thyroid function 
test were all within normal range. Mantoux test 
and chest X-ray excluded tuberculosis. Brain CT 
was normal. There were no other signs or 
symptoms suggestive of infection during this time.  
Intramuscular procyclidine 10mg temporarily 
improved his cognition (ECAQ 5/11) but soon 
deteriorated again (ECAQ 1/11). All the 
medications were stopped and he was treated as 
an in-patient. There was no further recurrence of 
extrapyramidal side effect despite the termination 
of benzhexol. Adequate hydration and abstinence 
from any drugs with anticholinergic and/or 
antidopaminergic action was ensured. The 
delirium resolved in 3 weeks following the 
termination of oral medication or 4 weeks after 
the last flupenthixol decanoate administration. 
The constipation was resolving but the dry skin 
and mouth were still present at that time. 
Nevertheless, the cognitive deficit was still 
present. His thought process was slow, and most 
of the time he could not answer simple questions. 
The cognitive function gradually improved. At 6, 8 
and 11 weeks post flupenthixol decanoate 
administration, the ECAQ scores were 6/11, 8/11 
and 11/11, respectively. Figure 1 illustrated the 
cognitive improvement experienced by the patient. 
At 7 weeks he developed parotitis secondary to 
the dry mouth and was managed by the 
otorhinolaryngologist. The patient refused 
antipsychotic treatment until 6 months later when 
he had a relapse. Oral olanzapine 2.5 mg bis in die 
was started. The dosage was increased to 10mg 
omni nocte without any anticholinergic or 
extrapyramidal side effects. 
Discussion 
Flupenthixol, a thioxanthene, has an unarguably 
predominant antagonistic action at the dopamine 
receptors (5,6). As for the anticholinergic 
property, literatures had contradicting view 
whether the anticholinergic effect is moderate (6) 
or clinically insignificant (5). At the beginning, 
when the patient presented with cognitive deficit 
and parkinsonism, anticholinergic medication was 
increased due to the impression that it was due to 
the excessive dopamine antagonist effects of 
flupenthixol decanoate and haloperidol. 
Haloperidol was discontinued and benzhexol 
dosage was increased. However, the cognition 
deteriorated further and he succumbed into a 
delirium state.  
The dilemma faced by the clinician involved was 
due to the fact that the anticholinergic medication 
was indicated for the dopamine antagonist side 
effect but at the same time may cause a cognitive 
side effect. The administration of anticholinergic 
will improve the cognitive deficit due to dopamine 
blockade per se but may worsen it if the cause is 
via the anticholinergic mechanism. The 
administration of procyclidine helped clarifying 
the underlying mechanism. The sudden increase of 
anticholinergic activity after procyclidine injection 
resulted with an instant improvement of ECAQ 
score by 2. This is because the anticholinergic 
medication can indirectly increase the dopamine 
release into the synaptic cleft. The surge of 
Fig. 1. Comparison of written alternating sequencing task test, pentagons test, 
and clock drawing test at one week (above) and 11 weeks (below) post 
Flupenthioxol Decanoate injection. 
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dopamine neurotransmitter in the dorsolateral 
prefrontal cortex improves the cognition (1). 
However, the improvement was not sustainable as 
procyclidine itself aggravated the existing 
anticholinergic adverse effect of flupenthixol, thus 
worsening the cognitive impairment. 
The anticholinergic side effect was detrimental in 
this case. In the beginning, the benzhexol may 
contribute to the delirium state due to its 
combined effect with the flupenthixol. 
Considering its short elimination half-life of 3.7 
hours, the washout period is estimated to be only 
around one day (7). Instead, the delirium and 
cognitive deficit persisted far beyond that point, 
thus suggesting it is highly likely due to the 
anticholinergic effect of flupenthixol decanoate 
rather than benzhexol.  
To date, the literatures on anticholinergic property 
of flupenthixol did not specifically mention on the 
specific type of muscarinic receptors involved. 
However, from the apparent side effects of the 
patient, we postulated that the flupenthixol 
antagonized both central and peripheral 
muscarinic receptors. The M1 receptors are mainly 
responsible for both the executive function and 
submandibular gland secretion. Whereas the M3 
are the main receptors for the intestinal motility as 
well as submandibular and parotid gland secretion 
(8).  
The dopamine antagonist action was the least 
likely to be the main contributor in this case. 
Flupenthixol has a higher affinity towards D1, D2 
and D3 but less towards the D4 receptors. D2 
receptors are abundantly found in the mesolimbic 
and nigrostriatal pathways that contribute to the 
psychosis and extrapyramidal side effects, 
respectively. Whereas the D4 receptors are mainly 
in the prefrontal cortex, thus they are related to 
the cognitive effect especially the executive 
function (2,9). Theoretically therefore, the 
extrapyramidal side effect is more likely to occur 
compared to impaired cognition based on the 
dopamine affinity of flupenthixol. Instead, 
parkinsonism did not recur after stopping the 
anticholinergic medication and continuous slow 
release of flupenthixol decanoate. 
The patient most likely had an increased 
vulnerability towards severe anticholinergic side 
effect of flupenthixol. There were several factors 
behind this susceptibility. His age was the main 
contributing factor. Even in a non-diseased brain, 
the aging process may affect the structure of the 
muscarinic receptor thus decrease the 
acetylcholine volume and its receptors (10,11). 
This prompts the increased sensitivity towards 
acetylcholine. There was also an increased 
permeability of the blood-brain barrier and 
auxiliary leakages in old age especially those with 
neurodegenerative diseases (8). These permit the 
additional diffusion of flupenthixol particles into 
the brain and enhanced the anticholinergic 
repercussions. Schizophrenia itself is considered 
as a neurodegenerative disease with 60% showed 
an accelerated clinical deterioration despite being 
given the best treatment with favorable 
socioeconomic factor (12).  
The intramuscular flupenthixol decanoate half-life 
is 17 days and the repeated administration ensures 
that the washout period to be approximately three 
months (6). It is meant to have a prolonged 
desired antipsychotic effect through each single 
administration but unfortunately so does the 
undesired adverse effect. In view that the 
flupenthixol is a lipophilic drug, its main 
disadvantage for the elderly is the prolongation of 
the half-life and the presence of more active free 
fractions of flupenthixol. This will accentuate the 
side effect properties in the elderly who is 
biologically having more fat, less water and less 
albumin compared to the body of their younger 
counterpart (6). The washout period did correlate 
with the patient improvement of the ECAQ score 
that resumed back to the perfect score at 11 weeks 
post administration. In view of the long period of 
washout, the patient needed a long hospital stay 
until the delirium resolved and the cognition 
adequate for an independent daily activities. There 
was no consensus regarding the antidote for 
anticholinergic delirium and anticholinergic-
induced cognitive deficit up to date (10). 
However, a safe environment and supportive 
treatment are pivotal to prevent further 
complication. Fortunately, this condition is 
reversible. 
In conclusion; A cognitive deficit with 
superimposed delirium in a treated schizophrenia 
patient may cause a confusion and dilemma in 
correctly determining the cause and delivering the 
best treatment. A wrong postulation can lead to a 
detrimental consequence in this otherwise 
reversible condition. Thus, psychiatrist and 
physician shall be a ware of these possible 
sequelae of flupenthixol in a susceptible individual 
to prevent further complication. 
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